奥曲肽治疗晚期原发性肝癌的临床观察  

Clinical Study of Octreodide for advanced primary Liver Cancer

作　　者：张琳[1] 姜藻[1] 李苏宜[1] 王彩莲[1] 

机构地区：[1]东南大学附属中大医院肿瘤科,南京210009

出　　处：《临床肿瘤学杂志》2004年第5期514-516,共3页Chinese Clinical Oncology

摘　　要：目的 :观察生长抑素类似物奥曲肽治疗晚期肝癌的疗效及不良反应。方法 :全组共收集 4 5例患者。治疗组2 0例 ,,使用奥曲肽 0 1mg ,皮下注射 ,每 8小时一次 ,每周 5天 ,直至进展。对照组 2 5例 ,接受积极的支持治疗。 2个月进行 1次评价。结果 :治疗组 1例PR ,对照组 0例PR ,无显著性差异 (P >0 0 5 )。治疗组中位生存期为 7个月 ,对照组中位生存期为4个月 ,无显著性差异 (P >0 0 5 )。治疗组中位TTP为 5个月 ,对照组中位TTP为 3个月 ,有显著性差异 (P <0 0 5 )。生活质量治疗组较对照组有较明显提高 ,上消化道出血的发生治疗组明显减少。无明显副作用。结论 :奥曲肽治疗晚期肝癌有一定疗效。Objective:To evaluate the effect and toxicity of octreotide for advanced primary hepatic cancer.Methods:Forty-five patients were admitted.Twenty of patients were given octreotide at the dose of 0.1 mg three times a day for 5days a week,while twenty-five patients were given the best supportive care only.Results:There was no significant difference in the response rate between two group (P>0.05).One patient treated with octreotide was PR and no patient in the control group is PR or CR.Patients treated with octreotide had an advantage in duration of survival with a median survival time of 7 months vs 4 months in the control group,but there was no significant difference between the two groups(P>0.05).And the advantage of octreotide was also in media aliment development time with 5 months vs 3 months in the control group and there was significant difference between the two groups(P<0.05).Octreotide seems to improve the quality of life,decrease the happening of upper gastrointestinal hemorrhage and does not show evidently toxicity.Conclusion:Octreotide therapy seems to have a survival benefit in advanced hepatic cancer patients,though improvement was not especially satisfactory.

关 键 词：治疗组 对照组 奥曲肽 晚期原发性肝癌 中位生存期 晚期肝癌 PR TTP 临床观察 疗效 

分 类 号：R735[医药卫生—肿瘤] R554.6[医药卫生—临床医学]